Momenta Pharmaceuticals Inc (MNTA1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Craig A. Wheeler
Employees:
131
675 WEST KENDALL STREET, CAMBRIDGE, MA 02142
617 491-9700

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Momenta Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune disease. It sells its products include Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 6.243 Billion Shares Outstanding118.965 Million Avg 30-day Volume 3.558 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.82
Price to Revenue131.4338 Debt to Equity0.0 EBITDA-231.277 Million
Price to Book Value9.9982 Operating Margin-769.5531 Enterprise Value3.502 Billion
Current Ratio6.377 EPS Growth0.094 Quick Ratio6.083
1 Yr BETA 0.0 52-week High/Low 0.0 / Profit Margin-757.6151
Operating Cash Flow Growth-3.8456 Altman Z-Score14.968 Free Cash Flow to Firm -139.902 Million
View SEC Filings from MNTA1 instead.

View recent insider trading info

Funds Holding MNTA1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MNTA1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DOWNEY BRUCE

  • Director
No longer subject to file 2020-10-01 0

GEMAYEL GEORGES

  • Director
No longer subject to file 2020-10-01 0

GILMAN STEVEN C

  • Director
No longer subject to file 2020-10-01 0

STONER ELIZABETH

  • Director
No longer subject to file 2020-10-01 0

CARVAJAL ALEJANDRA CHIEF LEGAL OFFICER

  • Officer
No longer subject to file 2020-10-01 0

GUTIERREZ-RAMOS JOSE-CARLOS

  • Director
No longer subject to file 2020-10-01 0

ARROYO SANTIAGO SVP, CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2020-10-01 0

MANNING ANTHONY M. CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2020-10-01 0

KWON YOUNG CHIEF FINANCIAL & BUS. OFFICER

  • Officer
No longer subject to file 2020-10-01 0

BARLOW JANE F

  • Director
No longer subject to file 2020-10-01 0

FIER IAN CHIEF MFG AND PROGRAM OFFICER

  • Officer
No longer subject to file 2020-10-01 0

BELTRAMELLO JO ANN CHIEF HR AND INF. OFFICER

  • Officer
No longer subject to file 2020-10-01 0

GROGAN DONNA ROY

  • Director
No longer subject to file 2020-10-01 0

CIEPLINSKA AGNIESZKA CHIEF ACCOUNTING OFFICER (PAO)

  • Officer
No longer subject to file 2020-10-01 0

WHEELER CRAIG A PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2020-09-10 0

ROBERTSON MICHELLE CHIEF FINANCIAL OFFICER

  • Officer
6,813 2019-10-25 0

SULAT JAMES R

  • Director
54,090 2019-06-19 0

KOESTLER THOMAS P

  • Director
15,590 2019-06-19 0

FISHMAN COREY N.

  • Director
10,090 2019-06-19 0

KAUNDINYA GANESH VENKATARAMAN COO & CSO

  • Officer
495,145 2018-08-21 0

LEICHER BRUCE SVP & GENERAL COUNSEL

  • Officer
171,801 2018-08-21 0

STORER SCOTT M SVP, CFO

  • Officer
44,783 2018-02-12 0

OTTMER MATTHEW P. CHIEF OPERATING OFFICER

  • Officer
0 2017-02-07 0

SHEA RICHARD P SVP, CFO

  • Officer
119,906 2016-12-15 0

ROACH JAMES M. SENIOR VP, DEVELOPMENT AND CHI

  • Officer
155,381 2016-11-21 0

FANUCCI MARSHA

  • Director
14,500 2016-06-23 0

SHAPIRO BENNETT M

  • Director
10,834 2016-06-01 0

BISHOP JOHN E SENIOR VP, PHARMACEUTICAL SCIE

  • Officer
157,253 2016-05-19 0

FRANKEN MICHAEL PRESIDENT, BIOSIMILARS BUSINES

  • Officer
37,968 2015-12-11 0

CLARKE JOHN K

  • Director
0 2015-06-10 0

HUTT PETER BARTON

  • Director
6,725 2014-09-12 0

BRUGGER STEPHEN B CHIEF OPERATING OFFICER

  • Officer
264,918 2010-10-28 0

SASISEKHARAN RAM

  • Director
306,344 2010-07-26 0

CRANE ALAN L

  • FORMER DIRECTOR
No longer subject to file 2010-04-14 0

LANGER ROBERT

  • Director
950,022 2008-08-08 0

BARRETT PETER

  • Director
0 2008-06-05 0

REEDERS STEPHEN T

  • Director
483,157 2008-03-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Index Plus All-Cap Fund MNTA1 -2.0 shares, $-54.4 2020-03-31 N-PORT

Elevate your investments